Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study

Fig. 5

Forest plot of incidence rate ratios of cardiovascular outcomes by SGLT2i exposure and erythrocytosis. The incidence rate ratio of cardiovascular outcomes between periods of (i) SGLT2i exposure with erythrocytosis; (ii) SGLT2i exposure without erythrocytosis; (iii) absence of SGLT2i exposure with erythrocytosis; and (iv) absence of SGLT2i exposure without erythrocytosis, were estimated using conditional Poisson regression model with an offset for the length of the risk period, with adjustment of time-varying factors (age and the use of other anti-diabetic agents [sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP1 receptor agonists, and insulin])

Back to article page